← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
tremelimumab
L01FX20
Forms & Strengths
- intravenous injection 25mg/10mL
- intravenous injection 20mg/10mL
Adult Dosing
- intravenous infusion of 10mg/kg as a single dose
- repeat dosing every 90 days for maintenance
Pediatric Dosing
- safety and effectiveness not established
Indications
- unresectable or metastatic malignant melanoma
- hepatocellular carcinoma
Mechanism of Action
- monoclonal antibody binding to CTLA-4
- inhibiting T-cell activation and proliferation
Contraindications
- hypersensitivity to tremelimumab
- immunodeficiency disorders
Adverse Reactions
- immune-mediated rash
- diarrhea
- pruritus
- fatigue
Drug Interactions
- immunosuppressants may reduce efficacy
- concomitant use with vaccines not recommended
Curated Content: Needs Vetting Before Put to Clinical Use